Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

$- $-

Operating expenses:

Research and development 6,336 5,500

General and administrative 4,183 2,400

Total operating expenses 10,519 7,900

Loss from operations (10,519) (7,900)

Other income (expense), net 664 171

Net loss (9,855) (7,729)

Preferred stock dividends (125) (125)

Loss applicable to common shares $(9,980) $(7,854)

Loss per share:

Basic and diluted $(0.29) $(0.34)

Shares used in calculation of loss per share:

Basic and diluted 34,681 22,808

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

March 31, December 31,

2008 2007

ASSETS:

Cash and investment securities $84,694 $92,621

Cash - restricted 281 281

Facilities and equipment, net 1,085 1,121

Licensed products, net 9,717 10,021

Other assets 1,341 1,096

Total assets $97,118 $105,140

LIABILITIES AND SHAREHOLDERS' EQUITY:

Current liabilities $9,956 $9,474

Long term liabilities 5,606 6,561

Shareholders' equity 81,556
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Glenn Keet, ... The Changing Landscape of EMR/EHR Clinical Data Integration with ... taking place in Washington, DC on June 14th-18th. , ... of integrating EMR/EHR systems with EDC, and will examine ... brought by eSource and electronic health records/electronic medical records ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Visionsense Corp. announces,FDA 510(k) Clearance of ... The system is based on a miniature ... Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... MIS surgical,procedures that are under served by ...
... Therapeutics announced today,the initiation of a Phase ... orally bioavailable small molecule in development for ... I study will evaluate the safety,tolerability and ... blind, placebo controlled, single ascending dose design ...
... March 18 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... II study of,NGX267, a muscarinic agonist in development ... The company is conducting a randomized, double-blind,placebo-controlled, ... evaluate,the safety, tolerability and efficacy of this once-a-day ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... As drylands of the world become even drier, water will not ... the soil will likely be affected, and their imbalance could affect ... That includes people living in Arizona, who may be in for ... study published in Nature that details how soil changes ...
... teams at the Polytechnic Institute of New York University ... understand and influence the complex swimming behaviors of schooling ... of mechanical and aerospace engineering at NYU-Poly, published two ... These studies are the latest in a ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
Cached Biology News:Plant production could decline as climate change affects soil nutrients 2The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: